Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia

TerminatedOBSERVATIONAL
Enrollment

1,770

Participants

Timeline

Start Date

December 28, 2023

Primary Completion Date

June 25, 2024

Study Completion Date

June 25, 2024

Conditions
Transthyretin Amyloidosis Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Trial Locations (21)

Unknown

Research Site, Akhtubinsk

Research Site, Astrakhan

Research Site, Barnaul

Research Site, Beslan

Research Site, Chelyabinsk

Research Site, Izhevsk

Research Site, Kaluga

Research Site, Kazan'

Research Site, Khabarovsk

Research Site, Kirov

Research Site, Krasnodar

Research Site, Nizhny Novgorod

Research Site, Omsk

Research Site, Rostov-on-Don

Research Site, Smolensk

Research Site, Ufa

Research Site, Vladimir

Research Site, Vladivostok

Research Site, Volgograd

Research Site, Yaroslavl

Research Site, Yekaterinburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT06338839 - Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia | Biotech Hunter | Biotech Hunter